Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
1,503
result(s) for
"Jackson, Lisa"
Sort by:
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
A total of 33 participants who received both doses of the Moderna mRNA-1273 vaccine against SARS-CoV-2 had blood drawn over a period of 6 months after vaccination. SARS-CoV-2 neutralizing activity was maintained in all the patients through the entire period of follow-up. A half-life of 202 days was determined for the live-virus neutralization activity.
Journal Article
Running scared
\"Kate Summers' teenage son, Jon, has been having nightmares. Someone is chasing him, the footsteps drawing relentlessly nearer. Jon can't see the man's face. He only senses that danger is coming - and there's no way to stop it.... \"Never tell anyone he's not your boy,\" was the warning. And Kate hasn't. Not since the day fifteen years ago when she was offered what she most wanted - a healthy newborn baby. He was hers to keep, provided she moved far away, for good. She's kept her workd, raising Jon in a small Oregon town, lying to him for both their sakes. Despite his gift - or curse - of premontion, Jon hasn't divined that he wa adopted illegally. But now Kate's long-ago choices are engulfing the life she's tried to build... Daegan O'Rourke has come to this remote corner of the Pacific Northwest to find answers only Kate can give. He understands why she's wary of him, but there's a far greater threat at hand. Someone is tracking Jon down - ready to kill him and anyone who gets in the way. And convincing Kate to trust him, even once she knows the whole shocking truth, is Daegan's only hope of keeping them alive...\" -- Page 4 of cover.
Book
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults
•Pneumococcal conjugate vaccines elicit effective T cell dependent responses.•Conjugate and free polysaccharide vaccines were compared in older adults.•Conjugate responses were significantly greater for majority of serotypes.•Conjugate vaccine could provide enhanced immunity against pneumococcal disease.
Streptococcus pneumoniae is a major cause of morbidity and mortality among adults 50 years of age and older in the United States. Pneumococcal conjugate vaccines are efficacious against pneumococcal disease in children and may also offer advantages in adults.
We performed a randomized, modified double-blind trial that compared a single dose of 13-valent pneumococcal conjugate vaccine (PCV13) with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in 831 pneumococcal vaccine naive adults 60–64 years of age. An additional group of 403 adults 50–59 years of age received open-label PCV13. Anti-pneumococcal opsonophagocytic activity (OPA) titers were measured at baseline, and at 1 month and 1 year after vaccination.
In the randomized trial, the month 1 post-vaccination OPA geometric mean titers in the PCV13 group were statistically significantly higher than in the PPSV23 group for 8 of the 12 serotypes common to both vaccines and for serotype 6A, a serotype unique to PCV13, and were comparable for the other 4 common serotypes. The immune response to PCV13 was generally greater in adults 50–59 years of age compared to adults 60–64 years of age. OPA titers declined from 1 month to 1 year after PCV13 administration but remained higher than pre-vaccination baseline titers.
PCV13 induces a greater functional immune response than PPSV23 for the majority of serotypes covered by PCV13, suggesting that PCV13 could offer immunological advantages over PPSV23 for prevention of vaccine-type pneumococcal infection.
Journal Article
If she only knew
\"What if you were a stranger, even to yourself? In this riveting novel of suspense, ... author Lisa Jackson keeps readers guessing through every twist and turn when a shocking accident leaves one woman wondering who she is, what she has done-- and why she could be the next to die... \"--Page 4 of cover.
Book
PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection
PfSPZ-CVac combines ‘PfSPZ Challenge’, which consists of infectious Plasmodium falciparum sporozoites (PfSPZ), with concurrent antimalarial chemoprophylaxis. In a previously-published PfSPZ-CVac study, three doses of 5.12x10 4 PfSPZ-CVac given 28 days apart had 100% vaccine efficacy (VE) against controlled human malaria infection (CHMI) 10 weeks after the last immunization, while the same dose given as three injections five days apart had 63% VE. Here, we conducted a dose escalation trial of similarly condensed schedules. Of the groups proceeding to CHMI, the first study group received three direct venous inoculations (DVIs) of a dose of 5.12x10 4 PfSPZ-CVac seven days apart and the next full dose group received three DVIs of a higher dose of 1.024x10 5 PfSPZ-CVac five days apart. CHMI (3.2x10 3 PfSPZ Challenge) was performed by DVI 10 weeks after the last vaccination. In both CHMI groups, transient parasitemia occurred starting seven days after each vaccination. For the seven-day interval group, the second and third vaccinations were therefore administered coincident with parasitemia from the prior vaccination. Parasitemia was associated with systemic symptoms which were severe in 25% of subjects. VE in the seven-day group was 0% (7/7 infected) and in the higher-dose, five-day group was 75% (2/8 infected). Thus, the same dose of PfSPZ-CVac previously associated with 63% VE when given on a five-day schedule in the prior study had zero VE here when given on a seven-day schedule, while a double dose given on a five-day schedule here achieved 75% VE. The relative contributions of the five-day schedule and/or the higher dose to improved VE warrant further investigation. It is notable that administration of PfSPZ-CVac on a schedule where vaccine administration coincided with blood-stage parasitemia was associated with an absence of sterile protective immunity. Clinical trials registration : NCT02773979 .
Journal Article
See how she dies
Adria Nash meets with skepticism when she arrives at the home of the wealthy Danvers family intent on proving she is London Danvers, the heiress kidnapped many years earlier as a child, but she soon comes to realize there is someone does believe her--and is not at all pleased she has been found.
Book
Influenza Vaccine Effectiveness in the United States during the 2015–2016 Season
Among U.S. children during the 2015–2016 influenza season, the inactivated influenza vaccine was found to be approximately 60% effective in preventing influenza illness, whereas the live attenuated influenza vaccine was not found to be effective.
Journal Article
Whispers
\"Even a man as powerful as Dutch Holland can't keep a scandal buried forever. That's why he's summoned his children home to Oregon before announcing his run for governor. Sixteen years ago, his rival's son, Harley Taggert, drowned in the murky waters of Lake Arrowhead. Dutch needs to know if his three daughters played a part--before the press begins digging into the tragedy. But instead of helping with damage control, the Holland sisters' return is the catalyst for shocking new revelations. Claire Holland has never breathed a word about what happened that night. While Tessa was the wild child and Miranda smart and studious, Claire was romantic. She'd fallen in love with Harley, even became engaged to him. But complications abounded, including local bad boy Kane Moran. Now Claire learns that an investigative journalist is back in town too, planning to write a book about Harley's death. Soon rumors swirl of betrayal and jealousy. Another body is unearthed. And a sadistic killer prepares to tie up every loose end at last...\"--Page 4 of cover.
Book
2014-2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type
Background. Circulating A/H3N2 influenza viruses drifted significantly after strain selection for the 2014-2015 vaccines. Also in 2014-2015, the Advisory committee on Immunization Practices recommended preferential use of live attenuated influenza vaccine (LAIV) over inactivated influenza vaccine (IIV) among children aged 2-8 years. Methods. Vaccine effectiveness (VE) across age groups and vaccine types was examined among outpatients with acute respiratory illness at 5 US sites using a test-negative design, that compared the odds of vaccination among reverse transcription polymerase chain reaction-confirmed influenza positives and negatives. Results. Of 9311 enrollees with complete data, 7078 (76%) were influenza negative, 1840 (19.8%) were positive for influenza A (A/H3N2, n=1817), and 395 (4.2%) were positive for influenza B (B/Yamagata, n=340). The overall adjusted VE was 19% (95% confidence interval [CI], 10% to 27%) and was statistically significant in all age strata except those aged 18-64 years. The adjusted VE of 6% (95%CI, -5% to 17%) against A/H3N2-associated illness was not statistically significant, unlike VE for influenza B/Yamagata, which was 55% (95%CI, 43% to 65%). Among those aged 2-8 years, VE against A/H3N2 was 15% (95%CI, −16% to 38%) for IIV and -3% (CI, -50% to 29%) for LAIV; VE against B/Yamagata was 40% (95%CI, -20% to 70%) for IIV and 74% (95%CI, 25% to 91%) for LAIV. Conclusions. The 2014-2015 influenza vaccines offered little protection against the predominant influenza A/H3N2 virus but were effective against influenza B. Preferential use of LAIV among young children was not supported.
Journal Article